PHLPPs: Emerging players in metabolic disorders

Keerthana Balamurugan, Kanika Chandra, S. Sai Latha, M. Swathi, Manjunath B. Joshi, Parimal Misra, Kishore V.L. Parsa

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


That reversible protein phosphorylation by kinases and phosphatases occurs in metabolic disorders is well known. Various studies have revealed that a multi-faceted and tightly regulated phosphatase, pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP)-1/2 displays robust effects in cardioprotection, ischaemia/reperfusion (I/R), and vascular remodelling. PHLPP1 promotes foamy macrophage development through ChREBP/AMPK-dependent pathways. Adipocyte-specific loss of PHLPP2 reduces adiposity, improves glucose tolerance,and attenuates fatty liver via the PHLPP2–HSL–PPARα axis. Discoveries of PHLPP1-mediated insulin resistance and pancreatic β cell death via the PHLPP1/2–Mst1–mTORC1 triangular loop have shed light on its significance in diabetology. PHLPP1 downregulation attenuates diabetic cardiomyopathy (DCM) by restoring PI3K–Akt–mTOR signalling. In this review, we summarise the functional role of, and cellular signalling mediated by, PHLPPs in metabolic tissues and discuss their potential as therapeutic targets.

Original languageEnglish
Article number103317
JournalDrug Discovery Today
Issue number10
Publication statusPublished - 10-2022

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'PHLPPs: Emerging players in metabolic disorders'. Together they form a unique fingerprint.

Cite this